Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Acute myeloid leukemia (AML) treatment decisions often lack actionable molecular insights.
• Integrating multiomics and drug response data is crucial for personalized cancer medicine.

Purpose of the Study:

• To evaluate the clinical utility of a functional precision medicine tumor board (FPMTB) for acute myeloid leukemia (AML).
• To assess the efficacy of individually tailored therapies guided by ex vivo drug response and multiomics data.

Main Methods:

• Prospective generation of ex vivo drug-response and multiomics profiling data for 252 AML samples.
• Integration of clinical, molecular, and functional data by an FPMTB for treatment recommendations.
• Clinical implementation of FPMTB recommendations in relapsed/refractory AML patients.

Main Results:

• Actionable drug recommendations were identified for 97% of AML patients.
• Individually tailored therapies achieved a 59% objective response rate in 37 patients.
• Biomarkers for drug response, like IL15 overexpression and FLT3 inhibitor resistance, were identified.

Conclusions:

• Functional ex vivo drug testing provides clinically actionable insights for AML treatment.
• FPMTB integration of multiomics and drug response data enables personalized cancer medicine.
• Rapid generation of functional data facilitates timely clinical decision-making for AML patients.